|Articles|March 1, 2003

Benefits of PDT more far-reaching than previously expected

Orlando-Photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis Ophthalmics) is used widely to treat predominantly classic choroidal neovascularization (CNV) in age-related macular degeneration (AMD). The therapy, however, has met clinician resistance for treating occult CNV despite good visual results in the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study and the Verteporfin in Photodynamic Therapy (VIP) Trial, according to Joan W. Miller, MD.

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!

Latest CME

In-Person Event

20th Annual Controversies in Modern Eye Care

April 19, 2026

Benefits of PDT more far-reaching than previously expected

Newsletter

Related Content

Harrow completes acquisiton of Melt Pharmaceuticals

Coave Therapeutics reveals lead gene therapy program, CoTx-10

Foundation Fighting Blindness releases 4-year RUSH2A data to public

Opus Genetics doses first patient in phase 1/2 clinical trial, BIRD-1, evaluating OPGx-BEST1

AAO 2025: The rise of presbyopia research

Latest CME

20th Annual Controversies in Modern Eye Care

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME

(COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME

Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience

(COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation

Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience

(CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

(COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

(CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

(CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

(COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

(CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

(CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success

(CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

(COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

(COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

(COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Interventional Dry Eye: A Stepwise Treatment & Management Approach

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Expanding Treatment Options for Demodex Blepharitis: Patient-Centric Approaches to Therapy

Expanding Treatment Options for Demodex Blepharitis: Patient-Centric Approaches to Therapy

Burst CME™ Part 3: Initiating Early Intervention in Patients With Glaucoma Who Fail Pharmacological Therapy

(CME Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes

(CME Track) Burst CME™ Part 1: Insights Into Glaucoma and the Need for Early Intervention

Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs

Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs

Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis | Houston, TX

The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

(COPE Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes

(CME Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

(COPE Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

(CME Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

(COPE Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

Rapid Reviews in Retina™: Emerging Updates from Fall 2024 - Addressing the Wealth of New Data in Treatments for nAMD and DME

EnVision Summit

(CME Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches

(CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments

(CME Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery

Practical Approaches to Modern Dry Eye Treatment and Management

(COPE Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches

(CME Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

(CME Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care

(CME Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME

(CME Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes

(COPE Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care

(COPE Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME

(COPE Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes

(COPE Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments

(COPE Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery

(COPE Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

(COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Collaborative Care Symposium

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

Coave Therapeutics reveals lead gene therapy program, CoTx-10

Harrow completes acquisiton of Melt Pharmaceuticals